为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司--药明康德（股票代码：603259.SH/2359.HK）受邀出席第44届摩根大通医疗健康大会，并在主会场发表演讲。
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industries, has been invited to present at the 44th J.P. Morgan Healthcare Conference.
演讲时间 | Presentation Session：
北京时间：2026年1月14日（周三）11:30 PM – 1月15日 (周四) 0:10 AM
Pacific Time:January 14, 2026 (Wednesday) 07:30 AM - 08:10 AM
参与方式 | Participation：
网络直播（可在会议结束后30天内回放）| Webcast (replay active for up to 30 days):
https://jpmorgan.metameetings.net/events/healthcare26/sessions/317164-wuxi-apptec/webcast?gpu_only=true&kiosk=true
演讲材料将在会议结束后上传至公司官网:
The presentation will be available on the Company's website after the conference:
https://www.wuxiapptec.com/investors
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.
热门跟贴